Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
1505 studies found for:    Open Studies | "Breast Diseases"
Show Display Options
Rank Status Study
21 Recruiting Drug-Drug Interaction Study of Entinostat and Exemestane in Postmenopausal Women With ER+ Breast Cancer
Conditions: Breast Cancer;   Estrogen Receptor Positive Breast Cancer
Interventions: Drug: entinostat;   Drug: exemestane
22 Recruiting Randomized Study of Combination Chemotherapy With or Without Focused Microwave Thermotherapy Before Surgery in Treating Women With Large Breast Cancer Tumors
Condition: Breast Cancer
Interventions: Device: Focused Microwave Thermotherapy;   Drug: Chemotherapy (control)
23 Recruiting Comparison of the Breast Tumor Microenvironment
Conditions: Triple Negative Breast Cancer;   Hormone Receptor Positive Malignant Neoplasm of Breast
Interventions: Other: Breast tissue collection;   Other: Blood sample collection
24 Not yet recruiting Ibrance Real World Insights [IRIS]
Condition: Malignant Neoplasm of Breast
Intervention: Drug: Palbociclib
25 Not yet recruiting Olaparib & Radiation Therapy for Patients Triple Negative Breast Cancer (TNBC)
Conditions: Breast Neoplasms, Triple-Negative;   Breast Neoplasm Malignant Female;   Radiotherapy Side Effect
Interventions: Drug: Olaparib;   Radiation: Radiation therapy
26 Not yet recruiting Mirvetuximab Soravtansine in Localized Triple-Negative Breast Cancer (TNBC)
Condition: Malignant Neoplasm of Breast
Intervention: Drug: Mirvetuximab Soravtansine
27 Not yet recruiting 3HT With Taxol for Metastatic Breast Cancer
Condition: Malignant Neoplasm of Breast
Interventions: Drug: Neratinib;   Drug: Paclitaxel;   Drug: Pertuzumab;   Drug: Trastuzumab;   Drug: Doxorubicin;   Drug: Cyclophosphamide
28 Recruiting This Study in Patients With Different Types of Cancer (Solid Tumours) Aims to Find a Safe Dose of Xentuzumab in Combination With Abemaciclib With or Without Hormonal Therapies. The Study Also Tests How Effective These Medicines Are in Patients With Lung and Breast Cancer.
Conditions: Neoplasms;   Breast Neoplasms
Interventions: Drug: Xentuzumab;   Drug: Abemaciclib;   Drug: Letrozole;   Drug: Anastrozole;   Drug: Fulvestrant
29 Not yet recruiting A Phase 1, First-in-Human, Multi-Part Study of RAD140 in Postmenopausal Women With Hormone Receptor Positive Breast Cancer
Condition: Hormone Receptor Positive Malignant Neoplasm of Breast
Intervention: Drug: RAD140
30 Recruiting Optimizing Preventative Adjuvant Linac-Based Radiation: the OPAL Trial - Study of Hypofractionated Partial Breast Irradiation in Women With Early Stage Breast Cancer
Conditions: Malignant Neoplasm of Breast;   Breast Cancer
Interventions: Radiation: External Radiation Therapy;   Behavioral: Questionnaires
31 Recruiting Biobehavioral Effects of Hypnosis During Breast Cancer Surgery
Conditions: Malignant Neoplasm of Breast;   Breast Cancer
Interventions: Behavioral: Hypnosedation;   Behavioral: Empathic Conversation;   Behavioral: Questionnaires
32 Not yet recruiting Alternative Dosing Schedule of Palbociclib in Metastatic Hormone Receptor Positive Breast Cancer
Conditions: Breast Cancer;   Breast Carcinoma;   Cancer of Breast;   Malignant Tumor of Breast
Interventions: Drug: Palbociclib;   Drug: Letrozole;   Drug: Fulvestrant;   Procedure: Optional research biopsy;   Drug: Goserelin;   Procedure: Research blood draw
33 Recruiting Stand up to Cancer: MAGENTA (Making Genetic Testing Accessible)
Condition: Malignant Neoplasm of Breast
Interventions: Behavioral: Questionnaires;   Behavioral: Genetic Video;   Behavioral: Genetic Counselor;   Genetic: Saliva Collection;   Behavioral: Genetic Counseling;   Behavioral: Genetic Testing Results
34 Recruiting Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Gemcitabine and Carboplatin in Metastatic Triple Negative Breast Cancer (mTNBC)
Conditions: Triple-Negative Breast Neoplasms;   Breast Neoplasm;   Breast Cancer;   Triple-Negative Breast Cancer
Interventions: Drug: Trilaciclib;   Drug: Gemcitabine;   Drug: Carboplatin
35 Recruiting A Study of Anti-PD-1 (Pembrolizumab) + Hormonal Therapy in HR-positive Localized IBC Patients With Non-pCR to Neoadjuvant Chemotherapy
Conditions: Inflammatory Breast Cancer;   Malignant Neoplasm of Breast
Intervention: Drug: Pembrolizumab
36 Recruiting Pre-operative IRX-2 in Early Stage Breast Cancer (ESBC)
Conditions: Breast Neoplasm;   Breast Neoplasm, Male
Interventions: Drug: Cyclophosphamide;   Drug: Indomethacin;   Drug: Omeprazole;   Dietary Supplement: Multivitamin
37 Recruiting Effectiveness of Nefopam in Breast Cancer Surgery
Condition: Breast Neoplasm Malignant Primary
Interventions: Drug: Nefopam;   Drug: Normal Saline
38 Recruiting Shortening Adjuvant Photon Irradiation to Reduce Edema (SAPHIRE): Hypofractionated Versus Conventionally Fractionated Regional Nodal Irradiation for Invasive Breast Cancer
Condition: Malignant Neoplasm of Breast
Interventions: Radiation: Radiation Therapy;   Behavioral: Questionnaires
39 Recruiting Ultrasound and Near Infrared Imaging for Predicting and Monitoring Neoadjuvant Treatment
Conditions: Breast Cancer;   Breast Tumors;   Cancer of Breast;   Cancer of the Breast;   Malignant Neoplasm of Breast
Intervention: Device: Optical Tomography Using Near Infrared Diffused Light Assisted with Ultrasound
40 Recruiting A Phase II Study of Using Panitumumab/Carboplatin/Paclitaxel (PaCT) Followed by Anthracycline-Containing Regimen (AC) for New Triple-Negative Inflammatory Breast Cancer (TN-IBC)
Condition: Malignant Neoplasm of Breast
Interventions: Procedure: Breast Core Biopsy;   Drug: Paclitaxel;   Drug: Carboplatin;   Drug: Panitumumab;   Drug: Doxorubicin;   Drug: Cyclophosphamide;   Procedure: Mammogram;   Procedure: Ultrasound;   Other: Follow Up

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.